29. The molecular pathogenesis of RA
Tsokos. N Engl J Med 2004;350:2546–2548
McInnes et al. Nature Medicine 1997;3:189–195
Choy & Panayi. N Engl J Med 2001;344:907–916
Immune complexes
Complement fixation
Attract inflammatory
cell infiltrates
TNF-α, IL-1, IL-6
metalloproteinases
TNF-α
IL-2
IFN-γ
IL-17
RANKL
Articular cartilage
Production of metalloproteinases and other effector molecules
Migration of polymorphonuclear cells
Erosion of bone and cartilage
Pannus
Osteoclast Synoviocytes
Chondrocytes
MΦ
IL-4
IL-6
IL-10
RF, anti-CCP antibodies
IL-6, TNF-α,
IFN-γ, lymphotoxin
Plasma
cell
B cell
T cell
APC
30. Intervention with biologics can occur at several different
points in the immunopathogenic pathways of RA
Tsokos. N Engl J Med 2004;350:2546–2548
McInnes et al. Nature Medicine 1997;3:189–195
Choy & Panayi. N Engl J Med 2001;344:907–916
IL-4
IL-6
IL-10
RF, anti-CCP antibodies
Immune complexes
Complement fixation
Attract inflammatory
cell infiltrates
IL-6, TNF-α,
IFN-γ, lymphotoxin
TNF-α, IL-1, IL-6
metalloproteinases
TNF-α
IL-2
IFN-γ
IL-17
RANKL
Articular cartilage
Production of metalloproteinases and other effector molecules
Migration of polymorphonuclear cells
Erosion of bone and cartilage
Pannus
Osteoclast
Synoviocytes
Chondrocytes
Plasma
cell
B cell
MΦ
T cell
APC
T cell costimulation
modulator: Abatacept
Anti-CD20: Rituximab
TNF inhibitor: Infliximab,
adalimumab, certolizumab,
golimumab, etanercept
Anti-IL-6R: Tocilizumab